Isolating CD4+ and CD8+ T cells for improved drug efficacy and increased productivity

Isolating CD4+ and CD8+ T cell subsets is critical for controlling the ratio within a final drug product. It also has an impact on downstream steps such as cryopreservation after isolation. Achieving younger, less differentiated T cells is important for optimizing clinical outcomes. In this article, a method to achieve process flexibility characterized by high purity, favorable yield, and desired cell phenotype in both autologous and allogeneic cell therapy processes is explored. A platform technology to enable the isolation of CD4+ and CD8+ T cells with an active release mechanism for either clinical or commercial manufacturing is also described.

Please enter your email to access content Read now